部分T2-FLAIR错配征与WHO 4级胶质瘤IDH突变的关联:ReSPOND联盟研究结果
基于多机构ReSPOND联盟2165例成人WHO 4级胶质瘤术前MRI,评估部分T2-FLAIR错配征对IDH突变的诊断效能。该征象见于40例(1.8%),其中32例为IDH突变,敏感度26.4%、特异度99.6%、阳性预测值80.0%、阴性预测值95.8%。结论:部分T2-FLAIR错配征对WHO 4级胶质瘤IDH突变具有高度特异性。
要点
- 部分T2-FLAIR错配征在WHO 4级胶质瘤中罕见(1.8%),但出现时对IDH突变高度特异(99.6%)。
- 该征象敏感度低(26.4%),阴性不能排除IDH突变。
- 囊性成分和非强化实性成分与IDH突变相关,且与更长总生存期相关。
核心结论
- 部分T2-FLAIR错配征对WHO 4级胶质瘤IDH突变具有高度特异性。
研究设计与样本
- 多机构ReSPOND联盟分析2165例成人WHO 4级胶质瘤患者术前MRI,评估部分T2-FLAIR错配征的诊断效能。
关键影像表现/征象
- 部分T2-FLAIR错配征见于40例(1.8%)WHO 4级胶质瘤,其中32例为IDH突变型。
- 多因素logistic回归显示IDH突变与部分T2-FLAIR错配征(OR 5.715,95%CI [1.896, 17.221],p=0.002)、较年轻年龄(OR 0.911 [0.895, 0.927],p<0.001)、肿瘤中心位于额叶(OR 3.842 [2.361, 6.251],p<0.001)、无多中心性(OR 0.173 [0.049, 0.612],p=0.007)、存在囊性成分(OR 6.596 [3.023, 14.391],p<0.001)或非强化实性成分(OR 6.069 [3.371, 10.928],p<0.001)显著相关。
- 多因素Cox分析显示囊性成分(p=0.024)和非强化实性成分(p=0.003)与更长总生存期相关,而较老年龄(p<0.001)、中心位于额叶(p=0.008)、多灶性(p<0.001)和多中心性(p<0.001)与更短总生存期相关。
诊断标准与关键数值
- 部分T2-FLAIR错配征诊断IDH突变的敏感度26.4%、特异度99.6%、阳性预测值80.0%、阴性预测值95.8%(n=2165例WHO 4级胶质瘤)。
临床应用与阅片要点
- 在WHO 4级胶质瘤中观察到部分T2-FLAIR错配征时,高度提示IDH突变,可据此在报告中提示分子分型倾向。
- 该征象敏感度低,未见该征象不能排除IDH突变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: While the T2-FLAIR mismatch sign is highly specific for isocitrate dehydrogenase (IDH)-mutant, 1p/19q-noncodeleted astrocytomas among lower-grade gliomas, its utility in WHO grade 4 gliomas is not well-studied. We derived the partial T2-FLAIR mismatch sign as an imaging biomarker for IDH mutation in WHO grade 4 gliomas.
METHODS: Preoperative MRI scans of adult WHO grade 4 glioma patients (n = 2165) from the multi-institutional ReSPOND (Radiomics Signatures for PrecisiON Diagnostics) consortium were analyzed. Diagnostic performance of the partial T2-FLAIR mismatch sign was evaluated. Subset analyses were performed to assess associations of imaging markers with overall survival (OS).
RESULTS: One hundred twenty-one (5.6%) of 2165 grade 4 gliomas were IDH-mutant. Partial T2-FLAIR mismatch was present in 40 (1.8%) cases, 32 of which were IDH-mutant, yielding 26.4% sensitivity, 99.6% specificity, 80.0% positive predictive value, and 95.8% negative predictive value. Multivariate logistic regression demonstrated IDH mutation was significantly associated with partial T2-FLAIR mismatch (odds ratio [OR] 5.715, 95% CI [1.896, 17.221], p = 0.002), younger age (OR 0.911 [0.895, 0.927], p < 0.001), tumor centered in frontal lobe (OR 3.842, [2.361, 6.251], p < 0.001), absence of multicentricity (OR 0.173, [0.049, 0.612], p = 0.007), and presence of cystic (OR 6.596, [3.023, 14.391], p < 0.001) or non-enhancing solid components (OR 6.069, [3.371, 10.928], p < 0.001). Multivariate Cox analysis demonstrated cystic components (p = 0.024) and non-enhancing solid components (p = 0.003) were associated with longer OS, while older age (p < 0.001), frontal lobe center (p = 0.008), multifocality (p < 0.001), and multicentricity (p < 0.001) were associated with shorter OS.
CONCLUSION: Partial T2-FLAIR mismatch sign is highly specific for IDH mutation in WHO grade 4 gliomas.
引用
- Lee MD, Patel SH, Mohan S, et al. Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium. Neuroradiology. 2023. PMID: 37468750. doi:10.1007/s00234-023-03196-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。